Idiopathic pulmonary fibrosis: Is it a familial disease?

Current Opinion in Pulmonary Medicine

Volumn 12, Issue 5, 2006, Pages 312-317

  Allam, J Shirine ^a   Limper, Andrew H ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Familial interstitial pulmonary fibrosis; Genetics; Interstitial pulmonary fibrosis; Surfactant proteins

Indexed keywords

CYTOKINE; HLA ANTIGEN; INTERLEUKIN 6; SURFACTANT ASSOCIATED PROTEIN; SURFACTANT PROTEIN C; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR;

CIGARETTE SMOKING; CLINICAL FEATURE; DYSPNEA; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HAPLOTYPE; HETEROZYGOTE DETECTION; HUMAN; LUNG FIBROSIS; NONHUMAN; PATHOGENESIS; PNEUMONIA; REVIEW;

HUMANS; PEDIGREE; PULMONARY FIBROSIS;

EID: 33748145696     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000239546.24831.61     Document Type: Review

References (40)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161:646-664.
2. Sandoz E. A report of twins with fatal lung fibrosis, honeycomb lung and bronchiectasis [in German]. Beitr Path Anat 1907; 41:495.
3. Lee HL, Ryu JH, Wittmer MH, Hartman TE, et al. Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest 2005; 127:2034-2041. This paper describes the clinical and radiological characteristics of patients with familial pulmonary fibrosis and contrasts them with those of sporadic IPF.
4. Solliday NH, Williams JA, Gaensler EA, et al. Familial chronic interstitial pneumonia. Am Rev Respir Dis 1973; 108:193-204.
5. Peabody JW, Peabody JW Jr, Hayes EW, Hayes EW Jr. IPF: its occurrence in identical twin sisters. Dis Chest 1950; 18:330-334.
6. Marney A, Lane KB, Phillips JA 3rd, et al. Idiopathic pulmonary fibrosis can be an autosomal dominant trait in some families. Chest 2001; 120 (1 Suppl):56S.
7. Marshall RP, McAnulty RJ, Laurent GJ. The pathogenesis of pulmonary fibrosis: is there a fibrosis gene? Int J Biochem Cell Biol 1997; 29:107-120.
8. Murphy A, O'Sullivan BJ. Familial fibrosing alveolitis. Ir J Med Sci 1981; 150:204-209.
9. Koch B. Familial fibrocystic pulmonary dysplasia: observations in one family. Canad Med Ass J 1965; 92:801-808.
10. Marshall RP, Puddicombe A, Cookson WO, Laurent GJ. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 2000; 55:143-146.
11. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002; 57:338-342.
12. Loyd JE. Pulmonary fibrosis in families. Am J Respir Cell Mol Biol 2003; 29 (3 Suppl):S47-S50.
13. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Cell Mol Biol 2005; 172:1146-1152.
14. Huaux F, Louahed J, Hudspith B, et al. Role of interleukin-10 in the lung response to silica in mice. Am J Respir Cell Mol Biol 1998; 18:51-59.
15. Bitterman PB, Rennard SI, Keogh BA, et al. Familial idiopathic pulmonary fibrosis: evidence of lung inflammation in unaffected family members. N Engl J Med 1986; 314:1343-1347.
16. Selman M, King TE, Pardo A. American Thoracic Society European Respiratory Society American College of Chest Physicians Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-151.
17. Selman M, Pardo A. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003; 29 (3 Suppl):S93-S97.
18. Piguet PF, Ribaux C, Karpuz V, et al. Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol 1993; 143:651-655.
19. Smith RE, Strieter RM, Phan SH, et al. TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury. J Leukoc Biol 1998; 64:528-536.
20. Whyte M, Hubbard R, Meliconi R, et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med 2000; 162 (2 Pt 1):755-758.
21. Piguet PF, Vesin C, Grau GE, Thompson RC. Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine 1993; 5:57-61.
22. Pantelidis P, Fanning GC, Wells AU, et al. Analysis of tumor necrosis factoralpha, lymphotoxin-alpha, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 163:1432-1436.
23. Selman M, Lin HM, Montano M, et al. Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum Gen 2003; 113:542-550.
24. Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A 1991; 88:6642-6646.
25. Yong SJ, Adlakha A, Limper AH. Circulating transforming growth factorbeta(1): a potential marker of disease activity during idiopathic pulmonary fibrosis. Chest 2001; 120 (1 Suppl):68S-70S.
26. Renzoni E, Lympany P, Sestini P, et al. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum 2000; 43:1633-1640.
27. Hutyrova B, Pantelidis P, Drabek J, et al. Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 165:148-151.
28. Freeburn RW, Kendall H, Dobson L, et al. The 3′ untranslated region of tumor necrosis factor-alpha is highly conserved in idiopathic pulmonary fibrosis (IPF). Eur Cytokine Netw 2001; 12:33-38.
29. Turton CW, Morris LM, Lawler SD, Turner-Warwick M. HLA in cryptogenic fibrosing alveolitis. Lancet 1978; 1:507-508.
30. Fulmer JD, Sposovska MS, von Gal ER, et al. Distribution of HLA antigens in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1978; 118:141-147.
31. Geddes DM, Webley M, Brewerton DA, et al. Alpha 1-antitrypsin phenotypes in fibrosing alveolitis and rheumatoid arthritis. Lancet 1977; 2:1049-1051.
32. Hubbard R, Baoku Y, Kalsheker N, et al. Alpha1-antitrypsin phenotypes in patients with cryptogenic fibrosing alveolitis: a case-control study. Eur J Respir Dis 1997; 10:2881-2883.
33. Musk AW, Zilko PJ, Manners P, et al. Genetic studies in familial fibrosing alveolitis: possible linkage with immunoglobulin allotypes (Gm). Chest 1986; 89:206-210.
34. Amin RS, Wert SE, Baughman RP, et al. Surfactant protein deficiency in familial interstitial lung disease. J Pediatr 2001; 139:85-92.
35. Nogee LM, Dunbar AE 3rd, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344:573-579.
36. Thomas AQ, Lane K, Phillips J 3rd, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002; 165:1322-1328.
37. Whitsett JA. Genetic basis of familial interstitial lung disease: misfolding or function of surfactant protein C? Am J Respir Crit Care Med 2002; 165:1201-1202.
38. Whitsett JA, Weaver TE. Hydrophobic surfactant proteins in lung function and disease. N Engl J Med 2002; 347:2141-2148.
39. Wang WJ, Mulugeta S, Russo SJ, Beers MF. Deletion of exon 4 from human surfactant protein C results in aggresome formation and generation of a dominant negative. J Cell Sci 2003; 116 (Pt 4):683-692.
40. Tredano M, Griese M, Brasch F, et al. Mutation of SFTPC in infantile pulmonary alveolar proteinosis with or without fibrosing lung disease. Am J Med Genet A 2004; 126:18-26.